The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
about
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyInterleukin-6: an emerging regulator of pathological painConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsTherapeutic strategies for the clinical blockade of IL-6/gp130 signalingPrevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptorTumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategiesExpression of pancreatitis-associated protein after traumatic brain injury: a mechanism potentially contributing to neuroprotection in human brainContribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis.N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130.Interleukin-6 (IL-6) receptor/IL-6 fusion protein (Hyper IL-6) effects on the neonatal mouse brain: possible role for IL-6 trans-signaling in brain development and functional neurobehavioral outcomesMonocyte Subsets Coregulate Inflammatory Responses by Integrated Signaling through TNF and IL-6 at the Endothelial Cell Interface.A quantitative high-throughput screen for modulators of IL-6 signaling: a model for interrogating biological networks using chemical librariesInterleukin-6 Signaling Pathway and Its Role in Kidney Disease: An UpdateTranscriptional activation of endothelial cells by TGFβ coincides with acute microvascular plasticity following focal spinal cord ischaemia/reperfusion injury.Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cellsAnti-Inflammatory Agents for Cancer Therapy.A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data.Involvement of NF-κB/IL-6 Pathway in the Processing of Colorectal Carcinogenesis in Colitis MiceDeletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitisFibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin.Dietary blue pigments derived from genipin, attenuate inflammation by inhibiting LPS-induced iNOS and COX-2 expression via the NF-κB inactivation.Daily genetic profiling indicates JAK/STAT signaling promotes early hepatic stellate cell transdifferentiation.Autocrine effects of interleukin-6 mediate acute-phase proinflammatory and tissue-reparative transcriptional responses of canine bladder mucosaAngiogenic and innate immune responses triggered by PRP in tendon cells are not modified by hyperuricemia.Alternative splicing in multiple sclerosis and other autoimmune diseases.Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferationThe effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American womenIntestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitisAnti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma.Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cellsPositive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritisIL-6 Signaling in Myelomonocytic Cells Is Not Crucial for the Development of IMQ-Induced PsoriasisAttractive sheddingHHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in miceGenetics of asthma susceptibility and severityProlactin and Dehydroepiandrosterone Levels in Women with Systemic Lupus Erythematosus: The Role of the Extrapituitary Prolactin Promoter Polymorphism at -1149G/TInfluence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment.Dexamethasone and salbutamol stimulate human lung fibroblast proliferation.IL-6 and IL-17A degradation by mast cells is mediated by a serglycin:serine protease axis
P2860
Q24630541-8F984B9F-2477-4C44-9C12-D300AE90B626Q26748646-D54DF325-A099-44C6-BEBC-819D9FFC62D6Q26830569-D31D6A82-C33A-46AA-90F1-3BFC19A736B1Q27002391-54440A40-A088-43B7-8FE2-85CEE1A1451EQ27022976-9A46D99C-E0E6-4C5E-82A6-796C87F451DDQ28085631-D4D24167-7F54-4BFB-A09C-AA95E7DEC9C6Q28566140-945C3646-CBC6-47BE-842F-566225A71C11Q30318502-B8DBBE83-5AAA-4CDD-AD0C-0EC0666DA20EQ30382563-B0F58037-B4AD-4F98-B7F3-3ED39D9F3E72Q30445005-363FCD2F-26AA-4EE6-A03C-46EB440EA139Q30842307-16AB63DC-FBDB-481D-8EF3-97486BD5001AQ33492390-1A65ED5C-E2B3-4DDF-B7B8-A7479148A134Q33586501-88769AD8-C7F5-4967-98AE-DB226207EFEBQ33608063-0FA9A03C-D2B0-4D30-8EC4-CC809B76225CQ33634415-B6E042CC-3988-4F33-B168-19DF650D2E71Q33690450-14DB371C-7473-4BDE-BDDA-47E6AD3A68D1Q33744129-5F667242-7313-406F-BA55-F71B3822FE86Q33787296-7D74E19C-35A9-467F-8572-EE315480C0F4Q33908674-FE1CA752-73AA-4AF0-839C-75EA3FBC07E2Q34116480-B2D34035-DD49-4858-B9F2-3313CC65EAE2Q34164261-4718035B-4834-40D1-B20D-86BD1316CE0CQ34222153-3919251D-DBBE-4FF3-AFDE-9FBF7847A7A9Q34246947-C785D7D8-5013-4439-ADFD-BA7DD6BAB7D2Q34529396-CE038CF0-8B82-4C0E-BB49-A230C2F49D79Q34561165-D849D9E0-F791-45AC-BA5E-6D90732124A1Q34762634-60E41C36-C37E-478E-B3FE-D3CA13B0A1C0Q35083542-EE6F8F17-6579-4436-864D-890C83034BEFQ35100249-6DEB67BF-082A-43ED-8CA9-75F821E3B986Q35158224-CDB4BDFA-A3EC-41B6-AA7A-FD3A1E79FFC2Q35400401-A830BDDB-BA08-4F41-B4E8-4462C3EE6385Q35613184-8911F029-839D-4075-A0C9-B18E6CAA3B32Q35617594-7583D72F-1439-4B0B-A27D-95B2CA105428Q35964908-1E40E66C-283D-4366-AF94-94A16170E796Q35990669-1DEACC47-55FD-44B7-B312-65BB45F2F9C7Q36018434-9A597E3B-B10A-490B-8A56-B687D6172189Q36201283-45FC85D2-55B0-4C9D-A71A-AF0E24C31FD2Q36259961-A49108F7-87EE-4DD5-AFF8-E62487EAEB95Q36292019-126597F6-A5F6-4961-A3F8-F2F2324F9062Q36370961-DCDC1A2A-5E5B-4BAD-9195-231D203F4869Q36621030-02F9FBE5-81B4-4116-8606-0B4DFB19E430
P2860
The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
@ast
The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
@en
type
label
The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
@ast
The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
@en
prefLabel
The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
@ast
The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
@en
P2093
P2860
P1476
The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
@en
P2093
Dirk Seegert
Georg H Waetzig
Joachim Grötzinger
Jürgen Scheller
P2860
P304
P356
10.1517/14728222.11.5.613
P407
P577
2007-05-01T00:00:00Z